TrialCancer science2017

Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer.

Hiroya Taniguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.